Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) Announce Strategic Investment and Joint Venture to Advance First-in-Class Oncology Programs in China

Biond Biologics与广州-以色列生物技术基金（GIBF）宣布达成战略投资并成立合资公司，以在中国推进同类首创肿瘤项目的研发。

MISGAV, Israel and GUANGZHOU, China

以色列米斯加夫和中国广州

,

，

June 1, 2026

2026年6月1日

/PRNewswire/ -- Biond Biologics Ltd., a private clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases, and the Guangzhou-Israel Biotechnology Fund (GIBF), a leading life science investment fund, today announced a strategic $8 million investment together with the formation of a China-based joint venture to advance Biond's innovative oncology pipeline..

/PRNewswire/ -- Biond Biologics Ltd.（一家致力于开发癌症及免疫介导性疾病同类首创免疫疗法的非上市临床阶段生物技术公司）与广州-以色列生物技术基金（GIBF，一家领先的生命科学投资基金）今日宣布达成一项800万美元的战略投资，双方将共同成立一家位于中国的合资企业，以推进Biond的创新肿瘤研发管线。

The newly established joint venture will focus on accelerating the development of Biond's lead programs, including BND-67, a first-in-class therapy targeting CD28 shedding, as well as BND-22, a Phase 2 anti-ILT2 antibody and additional pipeline assets. The collaboration is designed to leverage Biond's differentiated oncology science together with GIBF's deep expertise in the Chinese biotechnology ecosystem, including clinical development, regulatory strategy, and local collaborations.

新成立的合资企业将致力于加速推进Biond的核心研发项目，包括靶向CD28脱落的同类首创疗法BND-67，以及处于II期临床的抗ILT2抗体BND-22与其他在研管线资产。此次合作旨在将Biond差异化的肿瘤学科研优势与GIBF在中国生物医药生态系统中深厚的专业能力相结合，涵盖临床开发、监管策略及本土合作等方面。

Through this partnership, Biond and GIBF aim to accelerate clinical execution, expand combination strategies, and maximize the value of Biond's pipeline within the Chinese market..

通过此次合作，Biond与GIBF旨在加速临床推进，拓展联合用药策略，并在中国市场最大化Biond研发管线的价值。

Biond's pipeline

Biond 的流水线

BND-22 is a Phase 2 anti-ILT2 checkpoint inhibitor designed to restore anti-tumor immunity by targeting the ILT2–HLA-G axis. BND-22 has demonstrated efficacy in heavily treated cancer patients in indications that hardly respond to Immuno-Oncology (IO) therapies, such as MSS-CRC, and is currently being evaluated in an ongoing Phase 2 study at MD Anderson Cancer Center..

BND-22是一款处于II期临床阶段的抗ILT2免疫检查点抑制剂，旨在通过靶向ILT2-HLA-G轴恢复抗肿瘤免疫。BND-22在对免疫肿瘤（IO）疗法几乎无应答（如MSS-CRC）的适应症中，已在多线治疗后的癌症患者身上展现出疗效，目前正于MD安德森癌症中心进行的一项II期临床研究中接受评估。

BND-67 is Biond's next-generation immunotherapy and a first-in-class asset targeting CD28 shedding, a novel immune evasion mechanism with the potential to redefine T-cell modulation in cancer. Given the central role of CD28 in T-cell activation, BND-67 introduces a fundamentally new approach to restoring immune responsiveness.

BND-67是Biond的下一代免疫疗法，也是同类首创的靶向CD28脱落的药物。CD28脱落是一种新型免疫逃逸机制，有望重新定义癌症中的T细胞调控。鉴于CD28在T细胞活化中的核心作用，BND-67引入了一种从根本上恢复免疫应答的全新方法。

By preserving CD28 signaling, it enhances effector T-cell activity while selectively inhibiting regulatory T-cell function, driving a potent and sustained anti-tumor response. The program is IND-ready, with a Phase 1 trial planned for Q2 2026..

通过维持CD28信号传导，它增强了效应T细胞的活性，同时选择性抑制调节性T细胞的功能，从而驱动强效且持久的抗肿瘤反应。该项目已具备IND申报条件，I期临床试验计划于2026年第二季度启动。

'Entering this strategic partnership with GIBF marks an important milestone in advancing our pipeline globally,' said Ori Shilo, CFO and Co-Founder of Biond Biologics. 'By combining our novel scientific approaches with GIBF's deep understanding of the Chinese biotech landscape, we are well-positioned to accelerate the development of our lead programs, BND-22 and BND-67, and expand their potential across key indications, leveraging both our clinical and business capabilities and the scale of the Chinese market.'.

Biond Biologics首席财务官兼联合创始人Ori Shilo表示：“与GIBF达成这一战略合作，标志着我们在全球推进研发管线方面迈出了重要里程碑。通过将我们创新的科学方法与GIBF对中国生物科技生态的深刻理解相结合，我们已具备充分优势，能够加速核心项目BND-22和BND-67的开发，并依托我们自身的临床与商业能力以及中国市场的规模优势，进一步拓展其在关键适应症中的潜力。”

'We are pleased to partner with Biond Biologics, a company developing highly differentiated therapies targeting novel immune pathways,' said Avner Lushi, Managing Partner of GIBF. 'The Chinese biotech market has rapidly evolved into a leading source of innovation, supported by high-quality clinical development and strong translational science.

“我们很高兴能与Biond Biologics公司达成合作，这是一家致力于开发针对新型免疫通路的高度差异化疗法的企业，”GIBF管理合伙人阿夫纳·卢希（Avner Lushi）表示。“在高质量临床开发与强大转化科学的推动下，中国生物科技市场已迅速发展成为领先的创新源泉。”

We believe that leveraging GIBF's unique investment model will enable the efficient advancement of Biond's assets and create meaningful value for both patients and stakeholders in the coming years. Together with Biond, we are also seeking additional collaborations across Asia to further expand Biond's capabilities and geographic footprint.'.

我们相信，借助GIBF独特的投资模式，将能够高效推进Biond资产的开发进展，并在未来几年为患者及利益相关方创造重要价值。与Biond携手，我们亦在亚洲积极寻求更多合作，以进一步拓展Biond的业务能力与业务版图。

About Biond Biologics

关于 Biond Biologics

Biond Biologics is a private, clinical-stage biotechnology company developing first-in-class immunotherapies targeting novel pathways across both the innate and adaptive immune systems. The company's pipeline includes clinical-stage oncology programs, alongside a growing portfolio of discovery and preclinical programs in immune-mediated diseases.

Biond Biologics 是一家非上市的临床阶段生物技术公司，致力于开发靶向先天与适应性免疫系统新型通路的同类首创免疫疗法。公司的研发管线涵盖临床阶段的肿瘤项目，以及不断扩充的针对免疫介导疾病的药物发现与临床前项目组合。

Biond was founded in 2016 by Tehila Ben Moshe, Ph.D., Ori Shilo, and a team of accomplished scientists and drug developers. .

Biond于2016年由Tehila Ben Moshe博士、Ori Shilo以及一支由杰出科学家和药物研发专家组成的团队共同创立。

www.biondbio.com

www.biondbio.com

About GIBF (Guangzhou-Israel Biotechnology Fund)

关于GIBF（广州-以色列生物技术基金）

The Guangzhou-Israel Biotechnology Fund (GIBF) is a specialized life science investment fund focused on advancing innovative biotechnology companies and technologies through strategic investment and development in the Chinese market. GIBF provides capital, regulatory expertise, and local operational capabilities to support global biotech companies in China.

广州-以色列生物技术基金（GIBF）是一支专业的生命科学投资基金，致力于通过在中国市场开展战略投资与发展，推动创新型生物技术公司及技术的进步。GIBF提供资金、监管专业知识及本地运营能力，以支持全球生物技术公司在中国的发展。

.

。

https://www.gibf-bio.com/en

https://www.gibf-bio.com/en

Media Contacts

媒体联系人

For Biond Biologics:

致拜恩德生物：

Tal Sines

塔尔·西内斯

VP Business Development

业务发展副总裁

+972-4 884 4337

+972-4 884 4337

[email protected]

[email protected]

For GIBF:

对于 GIBF：

Avner Lushi

阿夫纳·卢希

Chief Executive Officer

首席执行官

[email protected]

[email protected]

SOURCE Biond Biologics Ltd.; GIBF

来源：Biond Biologics有限公司；GIBF

21

二十一

%

百分之

more press release views with

通过……获得更多新闻稿浏览量

Request a Demo

申请演示